Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

vival as the primary endpoint in patients treated with first-line docetaxel chemotherapy; the other trial design investigates pain palliation as the primary endpoint in patients treated with second-line docetaxel chemotherapy.

OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

About the Special Protocol Assessment and Agreement Process

Under a Special Protocol Assessment (SPA), a company and the FDA can reach an agreement on the design and size of a clinical trial to support a regulatory submission. This agreement can be in writing and cannot be changed after the clinical trial begins except: (i) with written agreement of the company and the FDA; or (ii) if the director of the FDA reviewing division determines that "a substantial scientific issue essential to determining the safety or effectiveness of the drug" was identified after testing began.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effective
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... "Global N-acetylcysteine Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth ... N-acetylcysteine industry. The report provides a ... applications and industry chain structure. The N-acetylcysteine market ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... NEW YORK, Nov. 9, 2010 Reportlinker.com announces that ... catalogue: Biomarkers - technologies,markets and ... Summary This report follows ... that can be objectively measured and evaluated as an ...
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" or ... U.S. and China, today announced that NeoStem,s Chairman and CEO, ... at Moves Magazine,s 2010 Power Women Awards Dinner & Ceremony ... Street, New York City. This event marks ...
... Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards 2China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 2China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 3China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 4China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 5China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 6China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 7China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 8
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... diagnostics could be minutes particles of rust, iron oxide, ... silicon dioxide. These magnetic nanoparticles, a mere 29 to ... trap antibodies to the virus that causes cervical cancer ... According to scientists in Vietnam, it is relatively ...
... Scripps Research Institute scientists have converted adult skin ... to first go through the laborious process of generating ... lead to new treatments for a range of diseases ... heart disease, Parkinson,s, and Alzheimer,s disease. The work ...
... the dozens of antibiotics that followed it, streptococcus bacteria ... world. The reason: the superb evolutionary skills of this ... landmark paper published this week in Science , ... used full genome sequencing to identify the precise steps ...
Cached Biology News:Detecting lethal diseases with rust and sand 2Scripps Research scientists convert skin cells to beating heart cells 2Scripps Research scientists convert skin cells to beating heart cells 3New research traces evolutionary path of multidrug-resistant strep bacteria 2New research traces evolutionary path of multidrug-resistant strep bacteria 3
Sheep Serum US Origin...
Human LAIR2 Biotinylated Affinity Purified PAb...
... Lacks the mycobacteria found in Complete Freund's Adjuvant ... Incomplete, Freund's Adjuvant is used ... used to produce water-in-oil emulsions of immunogens. ... long-lasting antibody responses which can be attributed to ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: